Phone: +48 71 880 86 04

Pharmaxi Background and Experience

Pharmaxi LLC is a CRO launched in 2013 by an experienced team with a solid background in clinical trials. Currently, we have 34 employees on board, providing clinical trials for big pharmaceutical companies (Sanofi, AbbVie, Takeda and others).

Coverage

Pharmaxi conducts clinical trials in Poland, the Czech Republic, Ukraine, and Eastern Europe. If necessary, we can widen our coverage to other countries with trusted partners. Please let us know which countries you are interested in, and we will make preliminary negotiations and prepare the proposal.

Therapeutic areas

Over the years, we have completed projects in the fields of cardiology, endocrinology, gastroenterology, pulmonology, pediatrics, nephrology, gynecology, oncology, neurology, rheumatology, and orphan diseases. It is possible to conduct clinical trials in other therapeutic areas.

Our main advantages are:

There are strong advantages of clinical trials in Poland and Eastern Europe as our local healthcare systems are centralized. A significant benefit of centralization is recruitment in all therapeutic areas. Additionally, the approval process is easier and faster than what may be possible in other countries within the EU. Our doctors and other healthcare professionals are well-trained, so they can offer excellent clinical practice and high-quality data.

Table 1. Pharmaxi Essential Projects

Investigated Disease No. Pts No. Sites
Hepatitis C (Poland and Eastern Europe, Latvia, Lithuania, Estonia) 1,450 18
Diabetes (Poland and Eastern Europe) 890 40
Non alcoholic fatty liver disease (Poland and Eastern Europe) 1100 50
Pancreatitis (Poland and Eastern Europe, Khazakhstan) 220 16
Juvenile Rheumatoid Arthritis (Poland and Eastern Europe, Belarus) 450 32
Acute Pyelonephritis (Poland and Eastern Europe, Belarus, Romania, Bulgaria, Russia, Croatia) 416 28

Our team

team

While looking forward to hearing from you, we welcome any questions you may have — so please do not hesitate to contact us for further details. We are available to provide any additional information per your request.